Interim safety data on the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin® added to standard therapy in patients with lung cancer.
Interim safety data on the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin® added to standard therapy in patients with lung cancer.
Background: Venous thromboembolism (VTE) is common in lung
cancer patients and the incidence is increased by treatments. Lung
cancer patients often have advanced disease at presentation, as well
as co-morbidities, such as heart failure and chronic lung disease all
of which increase the risk of VTE. Low molecular weight heparin
(LMWH) has been used in the prophylaxis of VTE but there are
limited data on the use of LMWH as primary thromboprophylaxis
in cancer patients. Because of this and interesting animal data suggesting
that LMWH may be anti-metastatic, the effect of long term
LMWH on overall survival should be investigated.
S413
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Macbeth, Fergus R
2b96cf0d-ec05-4049-89f4-1268e869744f
Noble, Simon
be42d512-f03e-41bc-a1ab-c12dbf249836
Burns, Sarah
4e152d32-33f5-431e-9452-237752e22213
Maughan, Timothy S.
fb224abb-9c96-44d2-ad18-464c74271955
2009
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Macbeth, Fergus R
2b96cf0d-ec05-4049-89f4-1268e869744f
Noble, Simon
be42d512-f03e-41bc-a1ab-c12dbf249836
Burns, Sarah
4e152d32-33f5-431e-9452-237752e22213
Maughan, Timothy S.
fb224abb-9c96-44d2-ad18-464c74271955
Griffiths, Gareth, Macbeth, Fergus R, Noble, Simon, Burns, Sarah and Maughan, Timothy S.
(2009)
Interim safety data on the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin® added to standard therapy in patients with lung cancer.
.
Record type:
Conference or Workshop Item
(Other)
Abstract
Background: Venous thromboembolism (VTE) is common in lung
cancer patients and the incidence is increased by treatments. Lung
cancer patients often have advanced disease at presentation, as well
as co-morbidities, such as heart failure and chronic lung disease all
of which increase the risk of VTE. Low molecular weight heparin
(LMWH) has been used in the prophylaxis of VTE but there are
limited data on the use of LMWH as primary thromboprophylaxis
in cancer patients. Because of this and interesting animal data suggesting
that LMWH may be anti-metastatic, the effect of long term
LMWH on overall survival should be investigated.
This record has no associated files available for download.
More information
Published date: 2009
Identifiers
Local EPrints ID: 413096
URI: http://eprints.soton.ac.uk/id/eprint/413096
PURE UUID: 4b2429b5-3ea5-4929-af41-c6e7d535534b
Catalogue record
Date deposited: 15 Aug 2017 16:30
Last modified: 28 Sep 2023 01:45
Export record
Contributors
Author:
Fergus R Macbeth
Author:
Simon Noble
Author:
Sarah Burns
Author:
Timothy S. Maughan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
